-DOCSTART-	O

Title	O
:	O
Outpatient	O
management	O
of	O
asthma	O
with	O
regular	B-I
nebulized	I-I
beta	I-I
agonists	I-I
:	O
comparison	O
of	O
bitolterol	B-I
mesylate	I-I
and	O
isoproterenol	B-I
.	O

METHODS	O
:	O
In	O
this	O
multicenter	O
,	O
double	O
-	O
blind	O
trial	O
;	O
130	B-P
nonsteroid	I-P
-	I-P
dependent	I-P
patients	I-P
were	O
randomized	O
to	O
receive	O
one	O
of	O
the	B-I
two	I-I
treatments	I-I
concomitantly	O
with	O
their	O
regular	O
asthma	O
medications	O
.	O

On	O
study	O
days	O
,	O
at	O
the	O
beginning	O
of	O
the	O
study	O
and	O
after	O
2	O
and	O
4	O
weeks	O
,	O
treatments	O
were	O
given	O
in	O
the	O
office	O
or	O
laboratory	O
and	O
patients	O
were	O
monitored	O
with	O
pulmonary	B-O
function	I-O
tests	I-O
for	O
eight	O
hours	O
.	O

-DOCSTART-	O

Title	O
:	O
Therapeutic	O
strategies	O
in	O
acute	O
myelocytic	O
leukemia	O
:	O
a	O
status	O
report	O
of	O
the	O
experience	O
of	O
CALGB	O
.	O

Cancer	O
and	O
Leukemia	O
Group	O
B	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Prevention	O
of	O
migraine	O
with	O
flunarizine	B-I
and	O
acetylsalicylic	B-I
acid	I-I
.	O

A	O
double	O
-	O
blind	O
study	O
]	O
.	O

30	O
children	O
between	O
7	O
and	O
17	O
years	O
suffering	O
from	O
at	O
least	O
2	O
attacks	O
/	O
month	O
of	O
common	O
or	O
classical	O
migraine	O
since	O
more	O
than	O
1	O
year	O
were	O
studied	O
.	O

After	O
clinical	O
exclusion	O
of	O
symptomatic	O
headache	O
4	O
weeks	O
were	O
documented	O
by	O
means	O
of	O
a	O
migraine	O
diary	O
.	O

Prophylaxis	O
with	O
Calcium	O
entry	O
blocker	O
Flunarizine	O
(	O
Sibelium	O
)	O
or	O
Thromboxane	O
A	O
inhibitor	O
Acetylsalicylic	O
acid	O
(	O
ASS	O
)	O
was	O
carried	O
out	O
in	O
a	O
double	O
blind	O
design	O
for	O
3	O
months	O
.	O

Medication	O
was	O
given	O
as	O
one	O
dosage	O
in	O
the	O
evening	O
:	O
2	O
-	O
5	O
mg	O
/	O
kg	O
KG	O
ASS	O
or	O
5	O
-	O
10	O
mg	O
Flunarizine	O
.	O

Documented	O
attack	O
frequency	O
and	O
duration	O
were	O
controlled	O
at	O
monthly	O
physical	O
examinations	O
.	O

Final	O
results	O
showed	O
no	O
differences	O
in	O
significant	O
reduction	O
of	O
attack	O
frequency	O
or	O
symptoms	O
between	O
both	O
different	O
therapeutic	O
principals	O
.	O

72	O
.	O
4	O
%	O
(	O
ASS	O
73	O
.	O
3	O
%	O
;	O
Flunarizine	O
71	O
.	O
4	O
%	O
)	O
of	O
patients	O
were	O
attack	O
-	O
free	O
or	O
had	O
at	O
least	O
a	O
50	O
%	O
reduction	O
.	O

Migraine	O
frequency	O
of	O
initially	O
7	O
-	O
8	O
was	O
reduced	O
to	O
1	O
-	O
2	O
attacks	O
/	O
month	O
.	O

Duration	O
remained	O
constant	O
in	O
both	O
groups	O
(	O
1	O
-	O
3	O
h	O
)	O
.	O

Side	O
effects	O
were	O
slight	O
body	O
weight	O
gain	O
or	O
abdominal	O
pain	O
after	O
intake	O
,	O
prophylaxis	O
had	O
not	O
to	O
be	O
interrupted	O
therefore	O
.	O

Longtime	O
prognosis	O
is	O
not	O
yet	O
possible	O
because	O
the	O
time	O
of	O
observation	O
is	O
too	O
short	O
so	O
far	O
.	O

-DOCSTART-	O

Title	O
:	O
Intravenous	O
lignocaine	O
&	O
haemodynamic	O
responses	O
to	O
cystoscopy	O
.	O

-DOCSTART-	O

Title	O
:	O
Tinidazole	B-I
and	O
metronidazole	B-I
in	O
hepatic	O
amoebiasis	O
.	O

METHODS	O
:	O
Only	O
those	O
with	O
unequivocal	O
clinical	O
,	O
radiological	O
and	O
laboratory	O
evidence	O
of	O
hepatic	O
amoebiasis	O
were	O
included	O
;	O
diagnostic	B-O
and	O
therapeutic	B-O
aspiration	I-O
was	O
performed	O
where	O
necessary	O
.	O

15	O
patients	O
received	O
metronidazole	B-I
and	O
16	O
tinidazole	B-I
,	O
in	O
random	O
order	O
.	O

The	O
2	O
groups	O
were	O
comparable	O
.	O

Both	O
drugs	O
were	O
given	O
orally	O
in	O
a	O
single	O
daily	O
dose	O
of	O
2g	O
for	O
a	O
minimum	O
of	O
3	O
days	O
,	O
with	O
treatment	O
extended	O
if	O
considered	O
clinically	O
advisable	O
.	O

-DOCSTART-	O

Title	O
:	O
Postoperative	B-I
radiotherapy	I-I
in	O
breast	O
cancer	O
-	O
-	O
long	O
-	O
term	O
results	O
from	O
the	O
Oslo	O
study	O
.	O

METHODS	O
:	O
There	O
were	O
1115	B-P
patients	I-P
including	I-P
27	I-P
protocol	I-P
deviants	I-P
.	O

The	O
follow	O
-	O
up	O
time	O
is	O
11	O
-	O
20	O
years	O
.	O

In	O
the	O
first	O
part	O
a	B-C
conventional	I-C
roentgen	I-C
unit	I-C
was	O
used	O
,	O
and	O
in	O
the	O
second	O
part	O
a	B-I
60Co	I-I
unit	I-I
,	O
with	O
considerably	O
increased	O
dosage	O
and	O
altered	O
treatment	O
plan	O
.	O

-DOCSTART-	O

Title	O
:	O
Untoward	O
effects	O
of	O
fenfluramine	B-I
in	O
autistic	B-P
children	I-P
.	O

METHODS	O
:	O
To	O
evaluate	O
the	O
untoward	O
effects	O
of	O
fenfluramine	O
in	O
children	B-P
with	I-P
autism	I-P
,	O
12	B-P
subjects	I-P
were	O
systematically	O
studied	O
.	O

Medication	O
was	O
administered	O
in	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
cross	O
-	O
over	O
study	O
.	O

Parents	O
were	O
trained	O
in	O
monitoring	O
untoward	B-O
effects	I-O
.	O

These	O
observations	O
were	O
compiled	O
in	O
detailed	B-O
daily	I-O
notes	I-O
.	O

In	O
addition	O
,	O
four	O
cases	O
describing	O
unusual	B-O
effects	I-O
found	O
in	O
a	O
sample	O
of	O
170	O
patients	O
treated	O
with	O
fenfluramine	B-I
are	O
also	O
reported	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
randomized	O
study	O
of	O
fetal	O
abdominal	O
diameter	O
and	O
fetal	O
weight	O
estimation	O
for	O
detection	O
of	O
light	B-P
-	I-P
for	I-P
-	I-P
gestation	I-P
infants	I-P
in	I-P
low	I-P
-	I-P
risk	I-P
pregnancies	I-P
.	O

METHODS	O
:	O
An	O
additional	O
examination	O
was	O
performed	O
at	O
34	O
weeks	O
if	O
the	O
fetal	O
weight	O
in	O
the	O
32nd	O
week	O
was	O
estimated	O
to	O
be	O
less	O
than	O
95	O
%	O
of	O
the	O
expected	O
mean	O
weight	O
.	O

Light	O
-	O
for	O
-	O
gestational	O
age	O
(	O
LGA	O
)	O
was	O
suspected	O
if	O
the	O
estimated	O
birth	O
-	O
weight	O
was	O
less	O
than	O
85	O
%	O
of	O
the	O
expected	O
mean	O
birthweight	O
.	O

This	O
applied	O
to	O
186	B-P
uncomplicated	I-P
pregnancies	I-P
in	I-P
which	I-P
there	I-P
was	I-P
no	I-P
clinical	I-P
suspicion	I-P
of	I-P
poor	I-P
intrauterine	I-P
growth	I-P
.	O

These	O
pregnancies	O
were	O
randomly	O
allocated	O
to	O
a	O
treatment	O
group	O
(	O
AD	B-I
and	O
estimated	B-I
weight	I-I
reported	I-I
)	O
or	O
to	O
a	O
control	O
group	O
(	O
AD	B-C
and	O
estimated	B-C
weight	I-C
withheld	I-C
)	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Opposing	O
effects	O
of	O
propranolol	B-I
and	O
diltiazem	B-I
on	O
the	O
angina	O
threshold	O
during	O
an	O
exercise	O
test	O
in	O
patients	B-P
with	I-P
syndrome	I-P
X	I-P
]	O
.	O

METHODS	O
:	O
Patients	O
were	O
given	O
propranolol	B-I
(	O
160	O
mg	O
daily	O
)	O
,	O
diltiazem	B-I
(	O
360	O
mg	O
daily	O
)	O
and	O
placebo	B-C
for	O
2	O
weeks	O
,	O
using	O
a	O
randomized	O
single	O
blind	O
protocol	O
.	O

Upright	B-O
bicycle	I-O
ergometer	I-O
testing	I-O
was	O
performed	O
at	O
the	O
end	O
of	O
each	O
period	O
of	O
treatment	O
.	O

-DOCSTART-	O

Title	O
:	O
Domperidone	B-I
,	O
metoclopramide	B-I
,	O
and	O
placebo	B-C
.	O

All	O
give	O
symptomatic	O
improvement	O
in	O
gastroesophageal	O
reflux	O
.	O

METHODS	O
:	O
Patients	O
were	O
divided	O
into	O
two	O
groups	O
on	O
the	O
basis	O
of	O
a	O
dual	O
-	O
isotope	O
mixed	O
-	O
meal	O
study	O
of	O
their	O
gastric	O
emptying	O
(	O
GE	O
)	O
.	O

Group	O
I	O
had	O
normal	O
GE	O
and	O
group	O
II	O
delayed	O
GE	O
.	O

Nine	B-O
gastrointestinal	I-O
symptoms	I-O
were	O
assessed	O
for	O
frequency	B-O
and	O
severity	B-O
before	O
treatment	O
.	O

The	O
trial	O
had	O
three	O
1	O
-	O
month	O
treatment	O
periods	O
using	O
metoclopramide	B-I
10	O
mg	O
q	O
.	O
i	O
.	O
d	O
.	O
,	O
domperidone	B-I
20	O
mg	O
q	O
.	O
i	O
.	O
d	O
.	O
,	O
or	O
placebo	B-C
on	O
a	O
random	O
basis	O
.	O

Symptoms	B-O
were	O
reassessed	O
at	O
the	O
end	O
of	O
each	O
month	O
.	O

-DOCSTART-	O

Title	O
:	O
Evaluation	O
of	O
three	O
dosage	O
-	O
prediction	O
methods	O
for	O
initial	O
in	O
-	O
hospital	O
stabilization	O
of	O
warfarin	B-I
therapy	I-I
.	O

METHODS	O
:	O
Adult	B-P
inpatients	I-P
who	I-P
had	I-P
received	I-P
warfarin	I-P
sodium	I-P
10	I-P
mg	I-P
daily	I-P
for	I-P
less	I-P
than	I-P
three	I-P
days	I-P
were	O
eligible	O
for	O
the	O
study	O
.	O

After	O
receiving	O
their	O
third	O
warfarin	B-I
dose	O
,	O
patients	O
were	O
randomly	O
assigned	O
to	O
have	O
their	O
warfarin	B-I
dosages	O
adjusted	O
using	O
one	O
of	O
three	O
dosage	O
-	O
prediction	O
methods	O
:	O
by	O
analog	O
computer	O
(	O
n	O
=	O
31	O
)	O
,	O
linear	O
regression	O
(	O
n	O
=	O
22	O
)	O
,	O
or	O
empiric	O
dosing	O
by	O
the	O
physician	O
(	O
n	O
=	O
34	O
)	O
.	O

A	B-O
prothrombin	I-O
time	I-O
(	I-O
PT	I-O
)	I-O
ratio	I-O
(	I-O
patient	I-O
PT	I-O
divided	I-O
by	I-O
control	I-O
PT	I-O
)	I-O
between	O
1	O
.	O
3	O
and	O
2	O
.	O
5	O
was	O
considered	O
to	O
be	O
in	O
the	O
therapeutic	O
range	O
.	O

For	O
patients	O
who	O
achieved	O
a	B-O
stable	I-O
PT	I-O
ratio	I-O
(	O
defined	O
as	O
a	O
PT	O
ratio	O
between	O
1	O
.	O
3	O
and	O
2	O
.	O
5	O
that	O
varied	O
by	O
less	O
than	O
0	O
.	O
05	O
on	O
two	O
consecutive	O
days	O
or	O
by	O
less	O
than	O
0	O
.	O
1	O
on	O
three	O
consecutive	O
days	O
without	O
a	O
dosage	O
change	O
)	O
before	O
discharge	O
,	O
the	B-O
number	I-O
of	I-O
days	I-O
(	I-O
time	I-O
to	I-O
stabilization	I-O
)	I-O
from	O
administration	O
of	O
the	O
first	O
warfarin	B-I
dose	O
to	O
achievement	O
of	O
the	B-I
warfarin	I-I
dosage	O
that	O
produced	O
a	B-O
stable	I-O
PT	I-O
ratio	I-O
(	I-O
stabilization	I-O
dosage	I-O
)	I-O
was	O
compared	O
.	O

-DOCSTART-	O

Title	O
:	O
Controlled	O
trial	O
of	O
induction	O
of	O
labor	O
by	O
vaginal	B-I
suppositories	I-I
containing	O
prostaglandin	B-I
E2	I-I
.	O

METHODS	O
:	O
A	B-P
group	I-P
of	I-P
84	I-P
women	I-P
at	I-P
39	I-P
-	I-P
43	I-P
weeks	I-P
of	I-P
pregnancy	I-P
were	O
randomly	O
allocated	O
to	O
a	O
blind	O
trial	O
of	O
induction	O
of	O
labor	O
with	O
vaginal	B-I
suppositories	I-I
containing	O
inert	B-C
material	I-C
or	O
either	O
0	B-I
.	I-I
2	I-I
mg	I-I
or	O
0	B-I
.	I-I
4	I-I
mg	I-I
of	I-I
prostaglandin	I-I
E2	I-I
.	O

The	B-I
suppositories	I-I
were	O
self	O
-	O
administered	O
every	O
two	O
hours	O
during	O
waking	O
hours	O
on	O
two	O
successive	O
days	O
until	O
labor	O
started	O
or	O
15	O
had	O
been	O
used	O
.	O

-DOCSTART-	O

Title	O
:	O
Chronic	O
lateral	O
humeral	O
epicondylitis	O
-	O
-	O
a	O
double	O
-	O
blind	O
controlled	O
assessment	O
of	O
pulsed	B-I
electromagnetic	I-I
field	I-I
therapy	I-I
.	O

METHODS	O
:	O
Treatment	O
was	O
continued	O
for	O
a	O
minimum	O
period	O
of	O
eight	O
weeks	O
.	O

-DOCSTART-	O

Title	O
:	O
Beta	O
-	O
cytotrophic	O
effects	O
of	O
glucose	B-I
,	O
glucagon	B-I
,	O
and	O
tolbutamide	B-I
in	O
man	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
piracetam	B-I
on	O
regional	O
cerebral	O
blood	O
flow	O
and	O
mental	O
functions	O
in	O
patients	B-P
with	I-P
organic	I-P
dementia	I-P
.	O

METHODS	O
:	O
The	O
double	O
-	O
blind	O
crossover	O
design	O
included	O
nine	O
measurement	O
occasions	O
,	O
each	O
involving	O
rCBF	B-O
measurement	I-O
by	O
the	B-O
133	I-O
-	I-O
Xe	I-O
inhalation	I-O
method	I-O
,	O
ratings	B-O
of	I-O
symptoms	I-O
of	I-O
dementia	I-O
,	O
personality	B-O
changes	I-O
,	O
and	O
side	B-O
effects	I-O
,	O
and	O
a	B-O
psychometric	I-O
investigation	I-O
.	O

Three	O
investigations	O
were	O
included	O
in	O
each	O
of	O
three	O
treatment	O
periods	O
.	O

The	O
first	O
investigation	O
in	O
a	O
period	O
was	O
made	O
without	O
medication	O
.	O

Then	O
either	O
placebo	B-C
or	O
piracetam	B-I
4	O
.	O
8	O
g	O
/	O
day	O
or	O
9	O
.	O
6	O
g	O
/	O
day	O
was	O
given	O
during	O
four	O
weeks	O
with	O
measurements	O
after	O
2	O
weekks	O
and	O
4	O
weeks	O
.	O

There	O
were	O
intervals	O
of	O
4	O
weeks	O
without	O
medication	O
between	O
the	O
treatment	O
periods	O
.	O

-DOCSTART-	O

Title	O
:	O
Dipyrone	B-I
for	O
treatment	O
of	O
post	O
-	O
operative	O
pain	O
.	O

-DOCSTART-	O

Title	O
:	O
Letter	O
:	O
Cephaloridine	B-I
and	O
gentamicin	B-I
in	O
prophylaxis	O
of	O
surgical	O
wound	O
infection	O
.	O

-DOCSTART-	O

Title	O
:	O
Truncal	B-I
vagotomy	I-I
and	O
drainage	B-I
for	O
duodenal	O
ulcer	O
.	O

-DOCSTART-	O

Title	O
:	O
Persistent	O
phenothiazine	O
dyskinesia	O
treated	O
with	O
tetrabenazine	B-I
.	O

METHODS	O
:	O
Six	B-P
patients	I-P
with	I-P
persistent	I-P
phenothiazine	I-P
dyskinesia	I-P
were	O
treated	O
in	O
a	O
double	O
-	O
blind	O
controlled	O
trial	O
with	O
tetrabenazine	B-I
100	O
mg	O
in	O
divided	O
dosage	O
.	O

-DOCSTART-	O

Title	O
:	O
Propranolol	B-I
vs	O
acetazolamide	B-I
.	O

A	O
long	O
-	O
term	O
double	O
-	O
masked	O
study	O
of	O
the	O
effect	O
on	O
intraocular	O
pressure	O
and	O
blood	O
pressure	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
influence	O
of	O
beta	B-I
-	I-I
adrenoceptor	I-I
blockade	I-I
on	O
left	O
ventricular	O
function	O
.	O

METHODS	O
:	O
Cardiac	B-O
function	I-O
was	O
investigated	O
by	O
M	B-O
-	I-O
Mode	I-O
and	O
2D	B-O
-	I-O
echo	I-O
-	I-O
cardiography	I-O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
effect	O
of	O
Naftidrofuryl	B-I
on	O
ethanol	O
-	O
induced	O
liver	O
damage	O
in	O
chronic	B-P
alcoholic	I-P
patients	I-P
.	O

METHODS	O
:	O
A	O
prospective	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
trial	O
of	O
intramuscular	B-I
Naftidrofuryl	I-I
was	O
carried	O
out	O
on	O
32	B-P
randomly	I-P
selected	I-P
hospitalized	I-P
male	I-P
alcoholic	I-P
patients	I-P
with	I-P
clinical	I-P
,	I-P
biochemical	I-P
and	I-P
histological	I-P
evidence	I-P
of	I-P
hepatic	I-P
damage	I-P
.	O

Seventeen	O
patients	O
received	O
the	B-I
drug	I-I
(	O
40	O
mg	O
in	O
5	O
ml	O
i	O
.	O
m	O
.	O
three	O
times	O
daily	O
for	O
6	O
days	O
)	O
and	O
15	O
patients	O
received	O
a	B-C
placebo	I-C
(	O
5	O
ml	O
in	O
normal	O
saline	O
i	O
.	O
m	O
.	O
three	O
times	O
daily	O
for	O
6	O
days	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Bronchoscopic	O
findings	O
in	O
patients	B-P
with	I-P
a	I-P
complete	I-P
radiographic	I-P
regression	I-P
of	I-P
small	I-P
cell	I-P
bronchogenic	I-P
carcinoma	I-P
.	O

METHODS	O
:	O
Fibre	B-I
-	I-I
optic	I-I
bronchoscopy	I-I
was	O
performed	O
in	O
21	B-P
patients	I-P
with	I-P
small	I-P
cell	I-P
bronchogenic	I-P
carcinoma	I-P
who	I-P
demonstrated	I-P
a	I-P
complete	I-P
radiographic	I-P
regression	I-P
of	I-P
their	I-P
chest	I-P
lesions	I-P
after	I-P
3	I-P
-	I-P
4	I-P
months	I-P
of	I-P
combination	I-P
chemotherapy	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Double	O
-	O
blind	O
comparison	O
of	O
liquid	B-I
antacid	I-I
and	O
placebo	B-C
in	O
the	O
treatment	O
of	O
symptomatic	O
reflux	O
esophagitis	O
.	O

METHODS	O
:	O
We	O
report	O
a	O
double	O
-	O
blind	O
comparison	O
of	O
liquid	B-I
antacid	I-I
vs	O
placebo	B-C
in	O
the	O
treatment	O
of	O
reflux	O
esophagitis	O
in	O
32	B-P
patients	I-P
with	I-P
chronic	I-P
heartburn	I-P
.	O

Entry	O
criteria	O
included	O
the	O
presence	O
of	O
symptomatic	O
gastroesophageal	O
reflux	O
confirmed	O
by	O
both	O
an	O
acid	O
perfusion	O
(	O
Bernstein	O
)	O
test	O
and	O
by	O
intraesophageal	O
pH	O
probe	O
.	O

Drug	O
treatment	O
consisted	O
of	O
15	B-I
ml	I-I
(	I-I
80	I-I
mEq	I-I
)	I-I
doses	I-I
of	I-I
antacid	I-I
(	I-I
Maalox	I-I
Therapeutic	I-I
Concentration	I-I
,	I-I
William	I-I
H	I-I
.	I-I

Rorer	I-I
)	I-I
or	O
placebo	B-C
taken	O
7	O
times	O
daily	O
,	O
ie	O
,	O
1	O
and	O
3	O
hr	O
after	O
meals	O
and	O
at	O
bedtime	O
.	O

-DOCSTART-	O

Title	O
:	O
Adjuvant	B-I
therapy	I-I
of	O
breast	O
cancer	O
:	O
the	O
Southwest	O
Oncology	O
Group	O
experience	O
.	O

METHODS	O
:	O
In	O
fully	B-P
and	I-P
partially	I-P
evaluable	I-P
patients	I-P
with	I-P
a	I-P
68	I-P
-	I-P
month	I-P
median	I-P
follow	I-P
-	I-P
up	I-P
,	O
treatment	B-O
failures	I-O
have	O
occurred	O
in	O
27	O
%	O
of	O
172	O
receiving	O
CMFVP	B-I
and	O
47	O
%	O
of	O
186	O
women	O
given	O
L	B-I
-	I-I
PAM	I-I
(	O
p	O
=	O
0	O
.	O
002	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
comparison	O
of	O
an	B-I
aqueous	I-I
and	O
a	B-I
pressurized	I-I
nasal	I-I
spray	I-I
of	I-I
beclomethasone	I-I
dipropionate	I-I
in	O
the	O
management	O
of	O
seasonal	O
rhinitis	O
.	O

METHODS	O
:	O
Beclomethasone	B-I
dipropionate	I-I
(	O
200	O
micrograms	O
)	O
was	O
administered	O
twice	O
daily	O
for	O
a	O
treatment	O
period	O
of	O
2	O
weeks	O
.	O

-DOCSTART-	O

Title	O
:	O
Risk	O
of	O
infection	O
after	O
penetrating	O
abdominal	O
trauma	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
antihypertensive	B-I
drugs	I-I
on	O
cognitive	O
function	O
in	O
adolescents	O
.	O

METHODS	O
:	O
Twenty	B-P
-	I-P
four	I-P
adolescents	I-P
with	I-P
persistent	I-P
blood	I-P
pressure	I-P
elevation	I-P
(	I-P
greater	I-P
than	I-P
95th	I-P
%	I-P
)	I-P
on	I-P
placebo	I-P
were	O
randomized	O
double	O
blind	O
to	O
clonidine	B-I
or	O
hydrochlorothiazide	B-I
treatment	O
.	O

A	B-O
battery	I-O
of	I-O
cognitive	I-O
tests	I-O
were	O
performed	O
during	O
the	O
placebo	O
phase	O
and	O
after	O
16	O
weeks	O
of	O
active	O
therapy	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Tocolysis	O
with	O
hexoprenalin	B-I
and	O
salbutamol	B-I
in	O
a	O
clinical	O
comparison	O
]	O
.	O

METHODS	O
:	O
In	O
77	O
%	O
in	O
the	B-I
hexoprenalin	I-I
and	O
in	O
74	O
%	O
in	O
the	B-I
salbutamol	I-I
group	O
the	B-O
weight	I-O
of	I-O
the	I-O
newborn	I-O
was	O
greater	O
than	O
or	O
equal	O
to	O
2500	O
g	O
.	O

In	O
66	O
%	O
in	O
both	O
study	O
groups	O
the	B-O
birth	I-O
occurred	I-O
after	I-O
the	I-O
completed	I-O
37	I-O
weeks	I-O
of	I-O
gestation	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
antacids	B-I
on	O
intragastric	O
pH	O
in	O
healthy	B-P
subjects	I-P
and	I-P
duodenal	I-P
ulcer	I-P
patients	I-P
.	O

Influence	O
of	O
the	B-I
size	I-I
of	I-I
the	I-I
antacid	I-I
dose	I-I
and	O
of	B-I
anticholinergics	I-I
.	O

METHODS	O
:	O
The	O
studies	O
were	O
performed	O
in	O
healthy	B-P
subjects	I-P
with	I-P
MAO	I-P
less	I-P
than	I-P
30	I-P
mmol	I-P
/	I-P
h	I-P
and	I-P
in	I-P
duodenal	I-P
ulcer	I-P
patients	I-P
with	I-P
MAO	I-P
greater	I-P
than	I-P
35	I-P
mmol	I-P
/	I-P
h	I-P
.	O

Gastric	B-O
pH	I-O
was	O
recorded	O
using	O
radiotelemetric	B-O
technique	I-O
(	I-O
Heidelberg	I-O
capsule	I-O
)	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Two	O
blind	O
randomized	O
cross	O
-	O
over	O
trials	O
in	O
the	O
treatment	O
of	O
primary	O
open	O
angle	O
glaucoma	O
.	O

-DOCSTART-	O

Title	O
:	O
Poylmerized	B-I
whole	I-I
ragweed	I-I
:	O
an	O
improved	O
method	O
of	O
immunotherapy	O
.	O

METHODS	O
:	O
Nineteen	B-P
ragweed	I-P
-	I-P
sensitive	I-P
patients	I-P
were	O
randomized	O
into	O
2	O
groups	O
;	O
10	O
received	O
the	B-I
polymerized	I-I
form	I-I
and	O
9	O
received	O
the	B-I
monomeric	I-I
form	I-I
.	O

Four	O
parameters	O
were	O
followed	O
:	O
serum	B-O
-	I-O
specific	I-O
IgE	I-O
against	I-O
antigen	I-O
E	I-O
,	O
total	B-O
blocking	I-O
antibody	I-O
against	I-O
antigen	I-O
E	I-O
,	O
local	B-O
and	O
systemic	B-O
reactions	I-O
to	O
injection	B-I
therapy	I-I
,	O
and	O
symptom	B-O
score	I-O
indices	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Value	O
of	O
an	B-I
anal	I-I
dilator	I-I
after	O
anal	O
stretch	O
for	O
haemorrhoids	O
.	O

-DOCSTART-	O

Title	O
:	O
Multimodal	B-I
therapy	I-I
for	O
the	O
management	O
of	O
primary	O
,	O
nonmetastatic	O
Ewing	O
'	O
s	O
sarcoma	O
of	O
bone	O
:	O
an	O
Intergroup	O
Study	O
.	O

-DOCSTART-	O

Title	O
:	O
Corticosteroid	O
-	O
induced	O
osteopenia	O
and	O
vitamin	O
D	O
metabolism	O
.	O

Effect	O
of	O
vitamin	B-I
D2	I-I
,	O
calcium	B-I
phosphate	I-I
and	O
sodium	B-I
fluoride	I-I
administration	I-I
.	O

METHODS	O
:	O
Group	O
A	O
received	O
prednisone	B-I
plus	O
'	B-I
triple	I-I
-	I-I
treatment	I-I
'	I-I
(	O
vitamin	B-I
D2	I-I
45000	O
iu	O
twice	O
weekly	O
,	O
sodium	B-I
fluoride	I-I
50	O
mg	O
and	O
calcium	B-I
phosphate	I-I
4	O
.	O
5	O
g	O
daily	O
)	O
,	O
group	O
B	O
received	O
only	B-C
prednisone	I-C
.	O

The	O
study	O
was	O
undertaken	O
in	O
order	O
to	O
evaluate	O
the	O
effect	O
of	O
prednisone	B-I
-	I-I
and	O
triple	B-I
-	I-I
treatment	I-I
upon	O
bone	B-O
mineral	I-O
content	I-O
(	I-O
BMC	I-O
)	I-O
and	O
vitamin	B-O
D	I-O
metabolism	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Non	O
-	O
Hodgkin	O
'	O
s	O
malignant	O
lymphomas	O
:	O
treatment	O
of	O
localized	B-I
relapses	I-I
with	O
chemo	B-I
+	O
radio	B-I
+	O
BCG	B-I
-	I-I
therapy	I-I
.	O

-DOCSTART-	O

Title	O
:	O
Perception	O
of	O
social	B-I
interactions	I-I
in	O
depressed	B-P
psychiatric	I-P
patients	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Antibiotic	B-I
therapy	I-I
of	O
acute	O
exacerbations	O
of	O
chronic	O
bronchitis	O
.	O

A	O
controlled	O
study	O
using	O
tetracycline	O
.	O

METHODS	O
:	O
All	O
patients	O
were	O
sufficiently	O
ill	O
to	O
require	O
hospitalization	O
although	O
none	O
needed	O
ventilatory	O
support	O
;	O
the	O
presence	O
of	O
pneumonia	O
was	O
excluded	O
.	O

Treatment	O
consisted	O
of	O
bronchodilators	B-I
,	O
corticosteroids	B-I
,	O
and	O
either	O
tetracycline	B-I
,	O
500	O
mg	O
,	O
or	O
placebo	B-C
by	O
mouth	O
every	O
6	O
hours	O
for	O
1	O
week	O
.	O

Arterial	B-O
blood	I-O
gases	I-O
,	O
spirometric	B-O
tests	I-O
,	O
bacteriologic	B-O
evaluation	I-O
of	I-O
sputum	I-O
,	O
and	O
patient	O
and	O
physician	O
evaluation	O
of	O
the	B-O
severity	I-O
of	I-O
illness	I-O
were	O
assessed	O
at	O
the	O
beginning	O
and	O
end	O
of	O
the	O
study	O
.	O

-DOCSTART-	O

Title	O
:	O
Comparison	O
of	O
the	O
therapeutic	O
effects	O
of	O
adriamycin	B-I
alone	I-I
versus	O
adriamycin	B-I
plus	O
vincristine	B-I
versus	O
adriamycin	B-I
plus	O
cyclophosphamide	B-I
in	O
the	O
treatment	O
of	O
advanced	O
carcinoma	O
of	O
the	O
cervix	O
.	O

-DOCSTART-	O

Title	O
:	O
Intraoperative	B-I
microscopy	I-I
of	O
bile	O
-	O
-	O
is	O
it	O
useful	O
?	O
.	O

-DOCSTART-	O

Title	O
:	O
Inhibition	O
of	O
spontaneous	O
platelet	O
aggregation	O
and	O
adhesion	O
by	O
indobufen	B-I
(	I-I
K	I-I
3920	I-I
)	I-I
.	O

A	O
randomized	O
,	O
double	O
-	O
blind	O
crossover	O
study	O
on	O
platelet	O
,	O
coagulation	O
and	O
fibrinolysis	O
function	O
tests	O
.	O

-DOCSTART-	O

Title	O
:	O
Antipyrine	O
clearance	O
and	O
response	O
to	O
interferon	B-I
treatment	I-I
in	O
patients	B-P
with	I-P
chronic	I-P
active	I-P
hepatitis	I-P
C	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Reducing	O
the	O
risk	O
of	O
coronary	O
events	O
:	O
evidence	O
from	O
the	O
Scandinavian	O
Simvastatin	B-I
Survival	O
Study	O
(	O
4S	O
)	O
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
4	I-P
,	I-P
444	I-P
patients	I-P
with	I-P
angina	I-P
pectoris	I-P
or	I-P
previous	I-P
myocardial	I-P
infarction	I-P
and	I-P
serum	I-P
cholesterol	I-P
levels	I-P
of	I-P
213	I-P
-	I-P
310	I-P
mg	I-P
/	I-P
dl	I-P
(	I-P
5	I-P
.	I-P
5	I-P
-	I-P
8	I-P
.	I-P

0	I-P
mmol	I-P
/	I-P
liter	I-P
)	I-P
while	I-P
treated	I-P
with	I-P
a	I-P
lipid	I-P
-	I-P
lowering	I-P
diet	I-P
were	O
randomly	O
assigned	O
to	O
double	O
-	O
blind	O
treatment	O
with	O
simvastatin	B-I
or	O
placebo	B-C
.	O

-DOCSTART-	O

Title	O
:	O
Why	O
are	O
there	O
sometimes	O
concreteness	O
effects	O
in	O
memory	O
for	O
prose	O
?	O
.	O

METHODS	O
:	O
Four	O
experiments	O
explored	O
on	O
-	O
line	O
encoding	O
strategies	O
and	O
memory	B-O
for	I-O
high	I-O
imagery	I-O
and	O
low	B-O
imagery	I-O
texts	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Quantifying	O
the	O
extent	O
of	O
osteonecrosis	O
of	O
the	O
femoral	O
head	O
.	O

A	O
new	O
method	O
using	O
MRI	O
.	O

METHODS	O
:	O
After	O
the	O
initial	O
clinical	O
evaluation	O
,	O
including	O
plain	O
radiography	O
and	O
MRI	O
,	O
37	B-P
hips	I-P
with	I-P
early	I-P
-	I-P
stage	I-P
osteonecrosis	I-P
(	I-P
ON	I-P
)	I-P
in	I-P
33	I-P
patients	I-P
were	O
randomly	O
assigned	O
to	O
a	B-I
core	I-I
-	I-I
decompression	I-I
group	O
or	O
a	B-C
conservatively	I-C
-	I-C
treated	I-C
group	O
.	O

All	O
were	O
followed	O
regularly	O
by	O
clinical	B-O
evaluation	I-O
,	O
plain	B-O
radiography	I-O
and	O
MRI	B-O
at	O
intervals	O
of	O
three	O
months	O
.	O

The	B-O
extent	I-O
of	I-O
ON	I-O
was	O
estimated	O
on	O
the	B-O
basis	I-O
of	I-O
abnormal	I-O
signal	I-O
intensity	I-O
in	I-O
the	I-O
weight	I-O
-	I-O
bearing	I-O
portion	I-O
of	I-O
the	I-O
femoral	I-O
head	I-O
as	O
determined	O
from	O
a	B-O
combination	I-O
of	I-O
coronal	I-O
and	I-O
sagittal	I-O
MRIs	I-O
.	O

The	B-O
arc	I-O
of	I-O
the	I-O
necrotic	I-O
portion	I-O
in	I-O
the	I-O
mid	I-O
-	I-O
coronal	I-O
image	I-O
(	O
A	O
)	O
and	O
that	O
in	O
the	B-O
mid	I-O
-	I-O
sagittal	I-O
image	I-O
(	O
B	O
)	O
were	O
used	O
to	O
quantify	O
the	B-O
extent	I-O
of	I-O
necrosis	I-O
by	O
the	O
formula	O
:	O
(	O
A	O
/	O
180	O
)	O
x	O
(	O
B	O
/	O
180	O
)	O
x	O
100	O
.	O

-DOCSTART-	O

Title	O
:	O
Cisplatin	B-I
plus	O
etoposide	B-I
with	I-I
and	O
without	B-I
ifosfamide	I-I
in	O
extensive	O
small	O
-	O
cell	O
lung	O
cancer	O
:	O
a	O
Hoosier	O
Oncology	O
Group	O
study	O
.	O

METHODS	O
:	O
Patients	B-P
with	I-P
extensive	I-P
SCLC	I-P
with	I-P
a	I-P
Karnofsky	I-P
performance	I-P
score	I-P
(	I-P
KPS	I-P
)	I-P
>	I-P
or	I-P
=	I-P
50	I-P
and	I-P
adequate	I-P
renal	I-P
function	I-P
and	I-P
bone	I-P
marrow	I-P
reserve	I-P
were	O
eligible	O
.	O

Patients	O
with	O
CNS	O
metastases	O
were	O
eligible	O
and	O
received	O
concurrent	O
whole	O
-	O
brain	O
radiotherapy	O
.	O

Patients	O
were	O
randomized	O
to	O
receive	O
cisplatin	B-I
(	O
20	O
mg	O
/	O
m2	O
)	O
plus	O
etoposide	B-I
(	O
100	O
mg	O
/	O
m2	O
)	O
(	O
VP	O
)	O
both	O
given	O
intravenously	O
(	O
i	O
.	O
v	O
.	O
)	O
on	O
days	O
1	O
to	O
4	O
or	O
cisplatin	B-I
(	O
20	O
mg	O
/	O
m2	O
)	O
,	O
ifosfamide	B-I
(	O
1	O
.	O
2	O
g	O
/	O
m2	O
)	O
,	O
and	O
etoposide	B-I
(	O
75	O
mg	O
/	O
m2	O
)	O
(	O
VIP	O
)	O
all	O
given	O
i	O
.	O
v	O
.	O
on	O
days	O
1	O
to	O
4	O
.	O

Cycles	O
were	O
repeated	O
every	O
3	O
weeks	O
for	O
four	O
cycles	O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
of	O
Contractubex	B-I
gel	I-I
in	O
the	O
treatment	O
of	O
fresh	O
scars	O
after	O
thoracic	O
surgery	O
in	O
children	B-P
and	I-P
adolescents	I-P
.	O

METHODS	O
:	O
Patients	O
were	O
randomly	O
assigned	O
either	O
to	O
a	O
group	O
which	O
was	O
treated	O
topically	O
with	O
Contractubex	B-I
gel	I-I
(	O
Merz	O
+	O
Co	O
.	O
,	O
D	O
-	O
Frankfurt	O
/	O
Main	O
)	O
,	O
containing	O
10	B-I
%	I-I
onion	I-I
extract	I-I
,	O
50	B-I
/	I-I
U	I-I
of	I-I
sodium	I-I
heparin	I-I
per	O
one	O
g	O
of	O
gel	O
and	O
1	B-I
%	I-I
allantoin	I-I
,	O
or	O
to	O
a	O
group	O
receiving	O
no	B-C
treatment	I-C
.	O

The	O
treatment	O
began	O
on	O
average	O
26	O
days	O
after	O
the	O
operation	O
and	O
was	O
continued	O
for	O
one	O
year	O
.	O

The	B-O
scars	I-O
of	I-O
all	I-O
treated	I-O
and	O
untreated	B-O
patients	I-O
were	O
evaluated	O
at	O
monthly	O
intervals	O
.	O

The	B-O
appearance	I-O
of	I-O
the	I-O
scar	I-O
,	O
including	O
scar	B-O
type	I-O
and	O
scar	B-O
size	I-O
as	O
well	O
as	O
scar	B-O
colour	I-O
,	O
was	O
assessed	O
by	O
the	O
physician	O
.	O

-DOCSTART-	O

Title	O
:	O
Randomized	O
controlled	O
study	O
of	O
chemoprophylaxis	B-I
in	O
transurethral	O
prostatectomy	O
.	O

METHODS	O
:	O
Before	O
transurethral	O
prostatectomy	O
the	O
patients	O
were	O
randomized	O
into	O
3	O
groups	O
:	O
group	O
1	O
-	O
-	O
197	O
patients	O
given	O
single	B-I
-	I-I
dose	I-I
ceftriaxone	I-I
(	O
2	O
gm	O
.	O
)	O
,	O
group	O
2	O
-	O
-	O
203	O
patients	O
given	O
160	B-I
/	I-I
800	I-I
mg	I-I
.	I-I

trimethoprimsulfamethoxazole	I-I
and	O
group	O
3	O
-	O
-	O
199	O
controls	O
given	O
no	B-C
antimicrobial	I-C
prophylaxis	I-C
.	O

Patients	O
with	O
a	O
preoperative	O
indwelling	O
catheter	O
,	O
positive	O
urine	O
culture	O
,	O
signs	O
of	O
active	O
infection	O
or	O
preoperative	O
antibiotic	O
treatment	O
were	O
excluded	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
effect	O
of	O
patient	B-I
position	I-I
on	O
the	O
reproducibility	O
of	O
cardiac	O
output	O
measurements	O
.	O

METHODS	O
:	O
Prospective	O
,	O
two	O
-	O
group	O
quasi	O
-	O
experimental	O
design	O
.	O

Convenience	O
sample	O
.	O

The	O
study	O
involved	O
two	O
intensive	O
care	O
units	O
in	O
two	O
adult	O
acute	O
care	O
hospitals	O
.	O

Thirty	B-P
patients	I-P
admitted	I-P
to	I-P
the	I-P
intensive	I-P
care	I-P
unit	I-P
who	I-P
had	I-P
a	I-P
thermodilution	I-P
pulmonary	I-P
artery	I-P
catheter	I-P
in	I-P
place	I-P
.	O

Ages	O
ranged	O
from	O
39	O
to	O
80	O
years	O
(	O
mean	O
of	O
66	O
.	O
4	O
+	O
/	O
-	O
11	O
.	O
3	O
years	O
)	O
.	O

Thermodilution	B-O
cardiac	I-O
output	I-O
measurements	I-O
.	O

The	O
subjects	O
were	O
placed	O
in	O
one	O
of	O
two	O
groups	O
,	O
initially	O
by	O
flipping	O
a	O
coin	O
then	O
into	O
alternate	O
groups	O
.	O

Group	O
A	O
subjects	O
were	O
placed	O
supine	B-I
,	O
and	O
after	O
5	O
minutes	O
had	O
cardiac	B-O
output	I-O
measurements	I-O
performed	O
.	O

They	O
were	O
then	O
placed	O
in	O
the	B-I
45	I-I
-	I-I
degree	I-I
upright	I-I
position	I-I
,	O
and	O
after	O
an	O
additional	O
5	O
minutes	O
had	O
cardiac	B-O
output	I-O
measurements	I-O
performed	O
.	O

Group	O
B	O
subjects	O
were	O
first	O
placed	O
in	O
the	B-I
45	I-I
-	I-I
degree	I-I
upright	I-I
position	I-I
,	O
and	O
after	O
5	O
minutes	O
had	O
cardiac	B-O
output	I-O
measurements	I-O
performed	O
.	O

They	O
were	O
then	O
placed	O
in	O
the	B-I
supine	I-I
flat	I-I
position	I-I
,	O
and	O
after	O
an	O
additional	O
5	O
minutes	O
had	O
cardiac	B-O
output	I-O
measurements	I-O
performed	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Postoperative	B-I
analgesia	I-I
:	O
peridural	B-I
morphine	I-I
versus	O
sublingual	B-I
buprenorphine	I-I
.	O

Comparative	O
clinical	O
study	O
]	O
.	O

METHODS	O
:	O
The	O
study	O
was	O
conducted	O
on	O
44	B-P
patients	I-P
,	I-P
both	I-P
male	I-P
and	I-P
female	I-P
,	I-P
classified	I-P
as	I-P
ASA	I-P
II	I-P
and	I-P
III	I-P
.	O

